Mechanisms of HIF1 alpha mediated dysregulated skeletal muscle proteostasis in alcoholic liver disease

HIF1α介导的酒精性肝病骨骼肌蛋白稳态失调的机制

基本信息

  • 批准号:
    10579341
  • 负责人:
  • 金额:
    $ 17.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-01 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

The prevalence of alcohol use disorders and consequent tissue injury, primarily alcoholic liver disease (ALD) continue to increase. Skeletal muscle loss or sarcopenia is a consistent abnormality in patients with ALD and is associated with adverse clinical outcomes that include increased mortality, other complications of liver disease and poor post-liver transplant outcomes. We have recently reported more severe muscle loss and a greater rate of muscle loss in patients with alcoholic cirrhosis compared with those in other causes of cirrhosis. Despite the high clinical significance of sarcopenia in ALD there are no effective therapeutic options because the underlying mechanisms are not well understood. We also reported that ethanol, directly and indirectly via impaired hepatic ammonia disposal and consequent hyperammonemia, results in a sarcopenic phenotype with dysregulated protein homeostasis (proteostasis). In preliminary studies, we have shown mitochondrial dysfunction in response to ethanol and hyperammonemia. We also noted that ethanol results in cataplerosis or loss of tricarboxylic acid (TCA) cycle intermediates, specifically α-ketoglutarate (αKG) an inhibitor of HIF1α. Consistently, unbiased approaches (assay for transposase accessible chromatin sequencing), and targeted experiments showed oxygen independent stabilization of muscle hypoxia inducible factor-1α (HIF1α) with ammonia. In pilot studies, we observed an increased expression of REDD1, a transcriptional target of HIF1α and a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1) that maintains skeletal muscle proteostasis with functional responses. We also noted relative preservation of muscle mass during hyperammonemia in muscle specific deletion of HIF1α mice. These observations formed the basis for our hypothesis that ethanol induced hyperammonemia causes cataplerosis of αKG with oxygen independent stabilization and impaired proteostasis and sarcopenia. We will test this hypothesis by testing if ethanol stabilizes HIF1α in skeletal muscle, and determine the mechanisms of stabilization of muscle HIF1α. Ethanol treatment in vitro in myotubes and in vivo in mice with loss and gain of function of HIF1α and its regulatory molecules will be used for these studies We will also test how metabolic perturbations regulate HIF1α stabilization and consequent molecular and functional responses in our preclinical models. Validation of key observations will be done in human muscle tissue from our biorepository. The proposed studies will enhance our understanding of the mechanisms of sarcopenia in ALD and lay the foundation for targeted therapeutics. This award will provide the support and time for the applicant for a supervised research career development in translational research. The applicant works with NIAAA funded independent investigators in the Northern Ohio Alcohol Center and her mentor developed the field of sarcopenia in liver disease. The institutional environment is highly supportive of her career path towards becoming an independent physician scientist focusing on mechanistic approaches to address unmet clinical needs in patients with alcohol use disorders.
酒精使用障碍和随之而来的组织损伤的患病率,主要是酒精性肝病(ALD) 继续增加。骨骼肌丧失或肌肉减少症是 ALD 患者的一贯异常现象,并且 与不良临床结果相关,包括死亡率增加、肝病的其他并发症 以及肝移植术后效果不佳。我们最近报告了更严重的肌肉损失和更大的 与其他原因引起的肝硬化患者相比,酒精性肝硬化患者的肌肉损失率。尽管 ALD 中肌肉减少症的高度临床意义目前尚无有效的治疗选择,因为 根本机制尚不清楚。我们还通过直接和间接报道乙醇 肝氨处理受损和随之而来的高氨血症,导致肌少症表型 蛋白质稳态失调(蛋白质稳态)。在初步研究中,我们已经表明线粒体 对乙醇和高氨血症的反应功能障碍。我们还注意到乙醇会导致猝倒症或 三羧酸 (TCA) 循环中间体的损失,特别是 α-酮戊二酸 (αKG)(HIF1α 的抑制剂)。 始终如一的、公正的方法(转座酶可及染色质测序的测定)和有针对性的 实验表明肌肉缺氧诱导因子 1α (HIF1α) 的氧依赖性稳定 氨。在试点研究中,我们观察到 REDD1(HIF1α 的转录靶标)的表达增加 以及维持骨骼健康的哺乳动物雷帕霉素靶标复合物 1 (mTORC1) 的负调节因子 肌肉蛋白质稳态与功能反应。我们还注意到肌肉质量的相对保存 HIF1α 肌肉特异性缺失小鼠的高氨血症。这些观察结果构成了我们的基础 假设乙醇诱导的高氨血症导致 αKG 不依赖氧的猝倒症 稳定性和蛋白质稳态受损以及肌肉减少症。我们将通过测试乙醇是否 稳定骨骼肌中的 HIF1α,并确定肌肉 HIF1α 的稳定机制。乙醇 HIF1α 功能丧失和获得及其调节的体外肌管治疗和小鼠体内治疗 分子将用于这些研究我们还将测试代谢扰动如何调节 HIF1α 我们的临床前模型中的稳定性以及随后的分子和功能反应。验证密钥 观察将在我们的生物样本库的人体肌肉组织中进行。拟议的研究将增强 我们对 ALD 中肌肉减少症机制的理解为靶向治疗奠定了基础。 该奖项将为申请人在监督下的研究职业发展提供支持和时间 转化研究。申请人与 NIAAA 资助的俄亥俄州北部的独立调查员合作 酒精中心和她的导师开发了肝脏疾病中的肌肉减少症领域。制度环境 高度支持她成为一名独立医师科学家的职业道路,专注于 解决酒精使用障碍患者未满足的临床需求的机械方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nicole Welch其他文献

Nicole Welch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nicole Welch', 18)}}的其他基金

Mechanisms of HIF1 alpha mediated dysregulated skeletal muscle proteostasis in alcoholic liver disease
HIF1α介导的酒精性肝病骨骼肌蛋白稳态失调的机制
  • 批准号:
    10358594
  • 财政年份:
    2021
  • 资助金额:
    $ 17.91万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 17.91万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 17.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 17.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 17.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 17.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 17.91万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 17.91万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 17.91万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 17.91万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 17.91万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了